• Procedure started
  • Under evaluation
  • CHMP opinion
  • European Commission final decision

Overview

EMA recommends aligning doses of metamizole medicines and their use during pregnancy and breastfeeding

On 13 December 2018, following a review of medicines containing the painkiller metamizole, EMA recommended that the maximum daily dose of the medicine and the contraindications to its use in pregnancy or women who are breastfeeding should be harmonised for all products on the EU market. The recommendation addressed inconsistencies in the product information for metamizole medicines, which are marketed in many EU member states to treat severe pain and fever that cannot be controlled with other treatments.

The review was carried out by EMA’s human medicines committee (CHMP) at the request of Poland, which was concerned by the substantial differences in the recommendations on the use of metamizole in different EU countries, given that it is known the medicine may occasionally cause severe side effects, such as effects on the blood.

The Agency reviewed the available information on the way the medicine is distributed in the body, how it works and the limited data on its effects on the unborn child or breast-fed infant.

EMA’s recommendations include setting a maximum single dose by mouth of 1,000 mg, taken up to 4 times daily (a maximum daily dose of 4,000 mg), in patients from 15 years of age. Treatment should start at the lowest recommended dose and only be increased if needed. If given by injection the total daily dose should not exceed 5,000 mg. Doses in younger patients should be based on their body weight but some products may be unsuitable because of their strength.

Although metamizole has been on the market for nearly a century, evidence of its effects in pregnancy and breastfeeding is scarce. The review found little to suggest problems in early pregnancy, and single doses in the first 6 months might be acceptable if other analgesics cannot be used. However, there was some evidence of effects on the kidneys and circulation of the fetus if the medicine were used in the last 3 months of pregnancy, and the medicine should therefore not be used in this period. As a precaution, metamizole should not be used during breastfeeding because the infant may receive high amounts of the medicine in the milk relative to the infant’s weight.

EMA’s recommendations were forwarded to the European Commission, which issued a final legally binding decision valid across the EU on 20 March 2019.

  • EMA has completed a review of the painkiller metamizole, used in many EU countries to treat severe pain and fever that cannot be controlled with other treatments.
  • EMA has recommended changes to the product information of metamizole, to ensure that advice on the maximum daily doses and warnings not to use the medicine during the last 3 months of pregnancy or during breastfeeding are consistent across the EU. A summary of the recommended changes will be published on the EMA website.
  • Updated summaries of product characteristics (information for healthcare professionals) and package leaflets for patients which contain the new recommendations will be available nationally following the final legal decision issued by the European Commission.
  • Patients who have any concerns about their medication should consult their doctor or pharmacist.

Metamizole (also known as dipyrone) is an analgesic medicine (painkiller) that can also relieve fever and muscle spasm. It has been used for many decades in the EU by mouth, as suppositories or by injection, to treat severe pain and fever that cannot be controlled with other treatments.

Metamizole-containing medicines are available in Austria, Belgium, Bulgaria, Croatia, Czech Republic, Finland, Germany, Hungary, Italy, Latvia, Lithuania, Luxembourg, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia and Spain. They are marketed under a variety of names including Algifen, Algifen Neo, Algi-Mabo, Algoblock, Algocalmin, Algopyrin, Algozone, Alindor, Alkagin, Alvotor, Amizolmet, Analgin, Benalgin, Benlek, Berlosin, Buscapina Compositum, Dialgin, Dolocalma, Flamborin, Freshalgin, Gardan, Generalgin, Hexalgin, Litalgin, Locamin, Metagelan, Metalgial, Metamilan, Metamistad, Metapyrin, Metarapid, Nevralgin, Nodoryl, Nolotil, Novalgin, Novalgina, Novalgine, Novaminsulfon, Novocalmin, Panalgorin, Parakofdal, Piafen, Piralgin, Proalgin, Pyralgin, Pyralgina, Quarelin, Scopolan Compositum, Spasmalgon, Spasmoblok, Tempalgin and Tempimet.

The review of metamizole was initiated on 31 May 2018 at the request of Poland, under Article 31 of Directive 2001/83/EC.

The review has been carried out by the Committee for Medicinal Products for Human Use (CHMP), responsible for questions concerning medicines for human use, which has adopted the Agency’s opinion. The CHMP opinion was forwarded to the European Commission, which issued a final legally binding decision applicable in all EU Member States on 20 March 2019.

Metamizole Article-31 referral - EMA recommends aligning doses of metamizole medicines and their use during pregnancy and breastfeeding

български (BG) (102.51 KB - PDF)
español (ES) (74.79 KB - PDF)
čeština (CS) (96.72 KB - PDF)
dansk (DA) (74.35 KB - PDF)
Deutsch (DE) (76.96 KB - PDF)
eesti keel (ET) (73.6 KB - PDF)
ελληνικά (EL) (105.3 KB - PDF)
français (FR) (76.96 KB - PDF)
hrvatski (HR) (92.42 KB - PDF)
italiano (IT) (74.65 KB - PDF)
latviešu valoda (LV) (96.33 KB - PDF)
lietuvių kalba (LT) (97.85 KB - PDF)
magyar (HU) (93.11 KB - PDF)
Malti (MT) (98.64 KB - PDF)
Nederlands (NL) (74.77 KB - PDF)
polski (PL) (96.54 KB - PDF)
português (PT) (75.01 KB - PDF)
română (RO) (95.84 KB - PDF)
slovenčina (SK) (95.3 KB - PDF)
slovenščina (SL) (94.17 KB - PDF)
Suomi (FI) (74.5 KB - PDF)
svenska (SV) (75.12 KB - PDF)

Key facts

About this medicine

Approved name
Metamizole containing medicinal products
International non-proprietary name (INN) or common name
metamizole

About this procedure

Current status
European Commission final decision
Reference number
EMEA/H/A-31/1469
Type
Article 31 referrals

This type of referral is triggered when the interest of the Union is involved, following concerns relating to the quality, safety or efficacy of a medicine or a class of medicines.

Authorisation model
Nationally authorised product(s)

Key dates and outcomes

CHMP opinion date
13/12/2018
EC decision date
20/03/2019

All documents

Procedure started

Metamizole Article-31 referral - Start of referral

Metamizole Article-31 referral - Notification

Metamizole Article-31 referral - List of questions

Metamizole Article-31 referral - Timetable for the procedure

European Commission final decision

Metamizole Article-31 referral - Annex II

български (BG) (86.54 KB - PDF)
español (ES) (42.6 KB - PDF)
čeština (CS) (85.27 KB - PDF)
dansk (DA) (42.71 KB - PDF)
Deutsch (DE) (45.5 KB - PDF)
eesti keel (ET) (40.41 KB - PDF)
ελληνικά (EL) (90.69 KB - PDF)
français (FR) (44.49 KB - PDF)
hrvatski (HR) (81.7 KB - PDF)
italiano (IT) (42.9 KB - PDF)
latviešu valoda (LV) (84.68 KB - PDF)
lietuvių kalba (LT) (84.85 KB - PDF)
magyar (HU) (71.98 KB - PDF)
Malti (MT) (86.9 KB - PDF)
Nederlands (NL) (42.55 KB - PDF)
polski (PL) (69.71 KB - PDF)
português (PT) (31.25 KB - PDF)
română (RO) (85.36 KB - PDF)
slovenčina (SK) (71.9 KB - PDF)
slovenščina (SL) (79.44 KB - PDF)
Suomi (FI) (41.61 KB - PDF)
svenska (SV) (42.53 KB - PDF)

Metamizole Article-31 referral - CHMP assessment report

Metamizole Article-31 referral - Annex III

български (BG) (421.52 KB - PDF)
español (ES) (448.36 KB - PDF)
čeština (CS) (403.2 KB - PDF)
dansk (DA) (359.74 KB - PDF)
Deutsch (DE) (427.57 KB - PDF)
eesti keel (ET) (362.85 KB - PDF)
ελληνικά (EL) (431.14 KB - PDF)
français (FR) (379.81 KB - PDF)
hrvatski (HR) (348.71 KB - PDF)
italiano (IT) (444.71 KB - PDF)
latviešu valoda (LV) (352.35 KB - PDF)
lietuvių kalba (LT) (414.39 KB - PDF)
magyar (HU) (414.99 KB - PDF)
Malti (MT) (417.06 KB - PDF)
Nederlands (NL) (376.03 KB - PDF)
polski (PL) (416.74 KB - PDF)
português (PT) (160.95 KB - PDF)
română (RO) (428.44 KB - PDF)
slovenčina (SK) (424.25 KB - PDF)
slovenščina (SL) (406.23 KB - PDF)
Suomi (FI) (302.59 KB - PDF)
svenska (SV) (365.04 KB - PDF)

Metamizole Article-31 referral - Annex I

български (BG) (522.21 KB - PDF)
español (ES) (475.94 KB - PDF)
čeština (CS) (419.95 KB - PDF)
dansk (DA) (359.32 KB - PDF)
Deutsch (DE) (377.3 KB - PDF)
eesti keel (ET) (358.08 KB - PDF)
ελληνικά (EL) (409.54 KB - PDF)
français (FR) (363.71 KB - PDF)
hrvatski (HR) (378.99 KB - PDF)
italiano (IT) (376.19 KB - PDF)
latviešu valoda (LV) (414.31 KB - PDF)
lietuvių kalba (LT) (423.48 KB - PDF)
magyar (HU) (386.07 KB - PDF)
Malti (MT) (413.56 KB - PDF)
Nederlands (NL) (366.46 KB - PDF)
polski (PL) (408.04 KB - PDF)
português (PT) (178.74 KB - PDF)
română (RO) (402.42 KB - PDF)
slovenčina (SK) (388 KB - PDF)
slovenščina (SL) (406.08 KB - PDF)
Suomi (FI) (357.01 KB - PDF)
svenska (SV) (373.79 KB - PDF)

Metamizole Article-31 referral - EMA recommends aligning doses of metamizole medicines and their use during pregnancy and breastfeeding

български (BG) (102.51 KB - PDF)
español (ES) (74.79 KB - PDF)
čeština (CS) (96.72 KB - PDF)
dansk (DA) (74.35 KB - PDF)
Deutsch (DE) (76.96 KB - PDF)
eesti keel (ET) (73.6 KB - PDF)
ελληνικά (EL) (105.3 KB - PDF)
français (FR) (76.96 KB - PDF)
hrvatski (HR) (92.42 KB - PDF)
italiano (IT) (74.65 KB - PDF)
latviešu valoda (LV) (96.33 KB - PDF)
lietuvių kalba (LT) (97.85 KB - PDF)
magyar (HU) (93.11 KB - PDF)
Malti (MT) (98.64 KB - PDF)
Nederlands (NL) (74.77 KB - PDF)
polski (PL) (96.54 KB - PDF)
português (PT) (75.01 KB - PDF)
română (RO) (95.84 KB - PDF)
slovenčina (SK) (95.3 KB - PDF)
slovenščina (SL) (94.17 KB - PDF)
Suomi (FI) (74.5 KB - PDF)
svenska (SV) (75.12 KB - PDF)

Description of documents published

Please note that some of the listed documents apply only to certain procedures.

  • Overview - lay-language summary of the stage of the procedure
  • Notification – a letter from a Member State, the European Commission or the marketing authorisation holder requesting the initiation of the procedure
  • Scientific background – further background information from the triggering Member State on the issues leading to the initiation of the procedure (if applicable)
  • List of questions – questions agreed by the Committee requesting further information from the marketing authorisation holder(s) / applicant(s) to evaluate the issues identified
  • Timetable for the procedure – agreed timeframe to respond to the list of questions, to assess the issues and to adopt a conclusion
  • List of medicines concerned by the procedure – medicine(s) / active substance(s) concerned, and marketing authorisation holder(s) / applicant(s)
  • List of questions to be addressed by the stakeholders – call for data to be submitted by stakeholders (e.g. healthcare professionals, patient organisations, individual patients) (if applicable)
  • Stakeholder submission form – form to be used by stakeholders to submit data (if applicable)
  • Scientific conclusions – scientific conclusions of the PRAC and/or CHMP and/or CMDh
  • Assessment report – PRAC or CHMP assessment and conclusions on the issues investigated, including divergent positions (if applicable)
  • Divergent positions – divergent positions of the CHMP or CMDh members for pharmacovigilance procedures (if applicable)
  • Changes to the summary of product characteristics, labelling and package leaflet (amended sections or fully revised version) (if applicable)
  • Condition(s) to the marketing authorisation(s) – condition(s) for the safe and effective use of the medicine(s) (if applicable)
  • Condition for lifting the suspension – condition to be fulfilled for the suspension of the marketing authorisation(s) to be lifted (if applicable)
  • Timetable for implementation of CMDh position – agreed timeframe to submit and finalise the variation(s) implementing the outcome of the procedure (if applicable)

Note that older documents may have different titles.

Topics

How useful do you find this page?